SLAMF1/CD150 expression and topology in prostate and breast cancer cell lines


  • I.M. Gordiienko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • O.O. Lykhova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • V.M. Shcherbina R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • L.M. Shlapatska R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology



breast cancer, cell lines, prostate cancer, SLAMF1/CD150


Summary. Background: SLAMF1/CD150 receptor is aberrantly expressed in malignant hematopoietic cells compared to ubiquitous expression in their normal analogues. However, the data about CD150 expression and function outside the hematopoietic system are limited. The aim of this pilot study was to examine the profile of mRNA expression of CD150 isoforms and the protein topology in highly and low malignant breast (BC) and prostate cancer (PC) cell lines. Materials and Methods: The study was performed on BC T47D, MDA-MB-231, ВСС/Р and BC/ML cell lines and PC LNCap, Du-145 and PC-3 cell lines. The quantitative polymerase chain reaction was applied for study of CD150 isoforms mRNA expression and flow cytometry was used for determination of protein localization. Results: Analyzed BC cell lines did not express CD150 on the cell surface membrane (csCD150-), but more than 45% of cells were positive for CD150 cytoplasmic reaction (cyCD150+). The cyCD150 expression level in T47D cells of luminal BC subtype was higher than in basal BC cell lines MDA-MB-231, ВСС/Р and BC/ML. The PC cell lines expressed CD150 both on the cell surface and in cytoplasm. The highest number of csCD150+ and cyCD150+ cells was revealed in less aggressive androgen responsive, non-metastatic LNCap cell line. All studied BC and PC cell lines expressed mRNA of canonical transmembrane mCD150 and novel nCD150 isoforms but with different pattern of prevalence. Soluble CD150 isoform was revealed at the low level only in BCC/P BC cell line and LNCap, PC-3 PC cell lines. Conclusions: We have shown that BC and PC cell lines differentially expressed multifunctional receptor CD150 at the mRNA and protein levels that may indicate its association with the degree of their malignancy.


Cocks BG, Chang CC, Carballido JM, et al. A novel receptor involved in T-cell activation. Nature 1995; 376: 260–3.

Sidorenko SP, Clark EA. Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes. J Immunol 1993; 151: 4614–24.

Gordiienko I, Shlapatska L, Kovalevska L, Sidorenko SP. SLAMF1/CD150 in hematologic malignancies: Silent marker or active player? Clin Immunol 2019; 204: 14–22.

Yurchenko OV, Shlapatska LM, Skryma MR, et al. Immunohistochemical studies of CD150 expression in some human tumors. Exp Oncol 2003; 25: 186–90.

Romanets-Korbut O, Najakshin AM, Yurchenko M, et al. Expression of CD150 in tumors of the central nervous system: identification of a novel isoform. PLoS One 2015; 10: e0118302.

Shi D, Zhang Y, Tian Y. SLAMF1 Promotes methotrexate resistance via activating autophagy in choriocarcinoma cells. Cancer Manag Res 2020; 12: 13427–36.

Shlapatska LM, Gordiienko IM, Kovalevska LM, Sidorenko SP. The biological properties of HEK293T cell line transfected with mCD150 and nCD150 isoforms of CD150/SLAMF1 receptor. Biopolym Cell 2020; 36: 99–109.

Gordiienko I, Shlapatska L, Kholodniuk V, et al. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling. PLoS One 2017; 12: e0185940.

Gordiienko IM, Shlapatska LM, Kovalevska LM, Sidorenko SP. Differential expression of CD150/SLAMF1 in normal and malignant B cells on the different stages of maturation. Exp Oncol 2016; 38: 101–7.

Bezdieniezhnykh N, Lykhova A, Semesiuk N, et al. Establishment and characterization of new breast and ovari¬an cancer cell lines as a model for studying cellular plasticity in vitro. Exp Oncol 2016; 38: 94–100.

Lukianova NY, Andriiv AV, Chekhun VF. Correlation of iodine symporter expression in highly and low malignant cell lines of human breast cancer differed in their sensitivity to doxorubicin. Exp Oncol 2016; 38: 169–71.

Zadvornyi TV, Lukianova NY, Borikun TV, Chekhun VF. Effects of exogenous lactoferrin on phenotypic profile and invasiveness of human prostate cancer cells (DU145 and LNCaP) in vitro. Exp Oncol 2018; 40: 184–9.

Yalovenko TM, Todor IM, Lukianova NY, Chekhun VF. Hepcidin as a possible marker in determination of malignancy degree and sensitivity of breast cancer cells to cytostatic drugs. Exp Oncol 2016; 38: 84–8.

Yurchenko M, Skjesol A, Ryan L, et al. SLAMF1 is required for TLR4-mediated TRAM-TRIF-dependent signaling in human macrophages. J Cell Biol 2018; 217: 1411–29.

Avota E, Gulbins E, Schneider-Schaulies S. DC-SIGN mediated sphingomyelinase-activation and ceramide generation is essential for enhancement of viral uptake in dendritic cells. PLoS Pathog 2011; 7: e1001290.




How to Cite

Gordiienko, I., Lykhova, O., Shcherbina, V., & Shlapatska, L. (2023). SLAMF1/CD150 expression and topology in prostate and breast cancer cell lines. Experimental Oncology, 43(4), 312–316.



Original contributions

Most read articles by the same author(s)